佩米替尼片治疗胆管癌疗效如何？治疗时要注意什么

Cholangiocarcinoma is a malignant tumor originating from bile duct epithelial cells. It can be divided into two categories: intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma according to the location of occurrence. The incidence of cholangiocarcinoma has increased year by year in recent years, and surgery is the only treatment with curative potential. Pemetinib tablets (pemetinib) are a selective fibroblast growth factor receptor (FGFR) kinase inhibitors. It causes constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and reducing cell viability, thus preventing or slowing the spread of cancer cells. How effective is the treatment of cholangiocarcinoma? What should I pay attention to during treatment?

In the clinical trial of pemetinib tablets (pemetinib) code-named FIGHT-202, a total of 107 patients with FGFR2 fusion/rearrangement participated in the trial. All patients who received pemetinib tablets (pemetinib) had a certain response and achieved a certain degree of relief, which was specifically manifested as a reduction in tumor volume and an alleviation of complications.

The results of the study show that the median overall survival (OS) of pemetinib tablets (pemetinib) is 21.1 months. Compared with the historical average survival time of patients with previous second- and third-line treatments, the second-line treatment regimen of pemetinib tablets (pemetinib) fully extended the survival period of patients by more than three times. It can be seen that pemetinib tablets can prolong the survival period of patients, reduce the pain of the disease, have a positive effect on the patient's condition, and have a significant therapeutic effect.

Precautions for Pemetinib Tablets

Treatment with pemetinib tablets (pemetinib) can cause retinal pigment epithelial detachment. Therefore, patients should undergo eye examinations in the first 6 months of treatment and every 3 months thereafter. If they experience severe discomfort, they should go to the hospital in time.

Treatment with pemetinib tablets (pemetinib) may result in hyperphosphatemia. Patients should be monitored and prevented for hyperphosphatemia during treatment. Depending on the duration and severity of hyperphosphatemia, patients may need to consider dose reduction or permanent discontinuation of treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: